In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma

Recently, two phase III studies of bevacizumab, an anti-angiogenic, for newly diagnosed glioblastoma (GBM) patients were released. While they were unable to statistically significantly demonstrate that bevacizumab in combination with other therapies increases the overall survival of GBM patients, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkins-Daarud, Andrea, Rockne, Russell, Corwin, David, Anderson, Alexander R. A., Kinahan, Paul, Swanson, Kristin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535409/
https://www.ncbi.nlm.nih.gov/pubmed/26202682
http://dx.doi.org/10.1098/rsif.2015.0388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535409/
https://www.ncbi.nlm.nih.gov/pubmed/26202682
http://dx.doi.org/10.1098/rsif.2015.0388

Ejemplares similares